Transgene

Transgene Capital Expenditures

The Capital Expenditures (CapEx) of Transgene (TNG.PA) as of Nov 18, 2026 is -3.07 M EUR. In the previous year, Capital Expenditures (CapEx) was -2.67 M EUR — a change of 14.96% (lower).

Capital Expenditures

-3.07 MEUR

YoY

14.96%

Last updated:

Capital Expenditures (CapEx) of Transgene is 2024 -3.07 M EUR. Capital Expenditures (CapEx) of Transgene was 2023 -2.67 M EUR. It decreases by 14.96% lower compared to the previous year.

The Transgene Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2017
-432,000.00 EUR
Jan 1, 2018
-1.36 M EUR
Jan 1, 2019
-1.69 M EUR
Jan 1, 2020
-811,000.00 EUR
Jan 1, 2021
-671,000.00 EUR
Jan 1, 2022
-1.50 M EUR
Jan 1, 2023
-2.67 M EUR
Jan 1, 2024
-3.07 M EUR
The Transgene Capital Expenditures history
YEARCapital ExpendituresYoY
-3.07 MEUR+14.96%
-2.67 MEUR+78.16%
-1.50 MEUR+123.10%
-671,000.00EUR-17.26%
-811,000.00EUR-51.95%
-1.69 MEUR+24.21%
-1.36 MEUR+214.58%
-432,000.00EUR+1,500.00%
-27,000.00EUR-98.23%
-1.53 MEUR-38.00%
-2.46 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Capital Expenditures (CapEx) of Transgene is -3.07 M EUR in 2024.

Capital Expenditures (CapEx) of Transgene changed from -2.67 M EUR to -3.07 M EUR, representing a 14.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Transgene since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene